Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Published:2020-11 Issue:11 Volume:21 Page:1413-1422
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Provencio Mariano,Nadal Ernest,Insa Amelia,García-Campelo María Rosario,Casal-Rubio Joaquín,Dómine Manuel,Majem Margarita,Rodríguez-Abreu Delvys,Martínez-Martí Alex,De Castro Carpeño Javier,Cobo Manuel,López Vivanco Guillermo,Del Barco Edel,Bernabé Caro Reyes,Viñolas Nuria,Barneto Aranda Isidoro,Viteri Santiago,Pereira Eva,Royuela Ana,Casarrubios Marta,Salas Antón Clara,Parra Edwin R,Wistuba Ignacio,Calvo Virginia,Laza-Briviesca Raquel,Romero Atocha,Massuti Bartomeu,Cruz-Bermúdez Alberto

Funder

Novartis

Horizon 2020 Framework Programme

Comunidad de Madrid

Instituto de Salud Carlos III

European Social Fund

Horizon 2020

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines;Ramnath;Chest,2013

3. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint;Hellmann;Lancet Oncol,2014

4. Neoadjuvant PD-1 blockade in resectable lung cancer;Forde;N Engl J Med,2018

5. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial;Shu;Lancet Oncol,2020

Cited by 557 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A2ST-GCM: An adaptive spatio-temporal aware graph convolutional model for predicting pathological complete response in neoadjuvant therapy;Biomedical Signal Processing and Control;2025-01

2. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review;International Immunopharmacology;2024-11

3. The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer;Cancer Imaging;2024-09-10

4. Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study;Journal for ImmunoTherapy of Cancer;2024-09

5. The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study;Cancer Medicine;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3